Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Cyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation.

Núñez KG, Gonzalez-Rosario J, Thevenot PT, Cohen AJ.

Ochsner J. 2017 Spring;17(1):56-65.

2.

The prevalence and impact of brucellosis in patients with hepatitis delta virus infection: inside the Brucella outbreak with cirrhosis.

Suvak B, Dulger AC, Suvak O, Yesilyurt AÖ, Gultepe B, Guducuoglu H.

Arch Med Sci. 2017 Mar 1;13(2):377-382. doi: 10.5114/aoms.2017.65317. Epub 2017 Jan 20.

3.

Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Ozoya OO, Chavez J, Sokol L, Dalia S.

Ann Transl Med. 2017 Feb;5(3):39. doi: 10.21037/atm.2016.12.25. Review.

4.

Hepatic deficiency of the pioneer transcription factor FoxA restricts hepatitis B virus biosynthesis by the developmental regulation of viral DNA methylation.

McFadden VC, Shalaby RE, Iram S, Oropeza CE, Landolfi JA, Lyubimov AV, Maienschein-Cline M, Green SJ, Kaestner KH, McLachlan A.

PLoS Pathog. 2017 Feb 24;13(2):e1006239. doi: 10.1371/journal.ppat.1006239. eCollection 2017 Feb.

5.

Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients.

Korkmaz P, Usluer G, Ozgunes I, Kartal ED, Erben N, Alpat SN.

North Clin Istanb. 2014 Aug 3;1(1):26-32. doi: 10.14744/nci.2014.27247. eCollection 2014.

6.

Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.

González VM, Martín ME, Fernández G, García-Sacristán A.

Pharmaceuticals (Basel). 2016 Dec 16;9(4). pii: E78. doi: 10.3390/ph9040078. Review.

7.

Mutations in hepatitis B virus small S genes predict postoperative survival in hepatocellular carcinoma.

Peng L, Yang G, Wu C, Wang W, Wu J, Guo Z.

Onco Targets Ther. 2016 Dec 2;9:7367-7372. eCollection 2016.

8.

Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.

Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A.

World J Gastroenterol. 2016 Nov 7;22(41):9186-9195.

9.

Viral hepatitis in hemodialysis: An update.

Bernieh B.

J Transl Int Med. 2015 Jun-Sep;3(3):93-105. Epub 2015 Sep 30. Review.

10.

Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment.

Guo R, Mao H, Hu X, Zheng N, Yan D, He J, Yang J.

Sci Rep. 2016 Nov 15;6:37015. doi: 10.1038/srep37015.

11.

Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs.

Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J, Su L.

Sci Rep. 2016 Nov 7;6:36483. doi: 10.1038/srep36483.

12.

Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.

Van Hees S, Michielsen P, Vanwolleghem T.

World J Gastroenterol. 2016 Oct 7;22(37):8271-8282. Review.

13.

Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon.

Friedman RM, Contente S.

Pharmaceuticals (Basel). 2009 Dec 15;2(3):206-216. Review.

14.

Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection.

Ghasemi F, Rostami S, Ghayour-Mobarhan M, Meshkat Z.

Iran J Basic Med Sci. 2016 Jul;19(7):692-704. Review.

15.

Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication.

Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, Wu Y, Yu Y, Xiong Y, Su L.

Cell Rep. 2016 Sep 13;16(11):2846-54. doi: 10.1016/j.celrep.2016.08.026.

16.

Fluorescence based Aptasensors for the determination of hepatitis B virus e antigen.

Huang R, Xi Z, Deng Y, He N.

Sci Rep. 2016 Aug 8;6:31103. doi: 10.1038/srep31103.

17.

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis.

Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF.

Medicine (Baltimore). 2016 Jul;95(30):e4311. doi: 10.1097/MD.0000000000004311.

18.

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV).

Welker MW, Zeuzem S.

Visc Med. 2016 Apr;32(2):105-9. doi: 10.1159/000445152. Epub 2016 Apr 8. Review.

19.

Liver Failure due to Acute Viral Hepatitis (A-E).

Manka P, Verheyen J, Gerken G, Canbay A.

Visc Med. 2016 Apr;32(2):80-5. doi: 10.1159/000444915. Epub 2016 Apr 7. Review.

20.

Immune Activation in the Liver by Nucleic Acids.

Sun Q, Wang Q, Scott MJ, Billiar TR.

J Clin Transl Hepatol. 2016 Jun 28;4(2):151-7. doi: 10.14218/JCTH.2016.00003. Epub 2016 Jun 15. Review.

Supplemental Content

Support Center